US 11,666,073 B2
Deuterated caffeine and uses thereof
Bradford C. Sippy, Acton, MA (US)
Assigned to Lennham Pharmaceuticals, Inc., Concord, MA (US)
Appl. No. 17/618,855
Filed by Lennham Pharmaceuticals, Inc., Concord, MA (US)
PCT Filed Jun. 12, 2020, PCT No. PCT/US2020/037485
§ 371(c)(1), (2) Date Dec. 13, 2021,
PCT Pub. No. WO2020/252302, PCT Pub. Date Dec. 17, 2020.
Application 17/618,855 is a continuation in part of application No. 16/752,407, filed on Jan. 24, 2020, granted, now 10,765,130.
Application 16/752,407 is a continuation of application No. 16/452,316, filed on Jun. 25, 2019, granted, now 10,582,716.
Claims priority of provisional application 62/861,517, filed on Jun. 14, 2019.
Prior Publication US 2022/0248720 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A23L 27/30 (2016.01); A23L 27/20 (2016.01); A23L 27/21 (2016.01); A23L 27/00 (2016.01); A23L 33/15 (2016.01); A23L 33/175 (2016.01); A23L 2/56 (2006.01); A23L 2/60 (2006.01)
CPC A23L 2/56 (2013.01) [A23L 2/60 (2013.01); A23L 27/2054 (2016.08); A23L 27/21 (2016.08); A23L 27/31 (2016.08); A23L 27/88 (2016.08); A23L 33/15 (2016.08); A23L 33/175 (2016.08); A23V 2002/00 (2013.01); A23V 2200/33 (2013.01); A23V 2250/0638 (2013.01); A23V 2250/0644 (2013.01); A23V 2250/0652 (2013.01); A23V 2250/154 (2013.01); A23V 2250/161 (2013.01); A23V 2250/2108 (2013.01); A23V 2250/705 (2013.01); A23V 2250/706 (2013.01); A23V 2250/708 (2013.01); A23V 2250/7046 (2013.01); A23V 2250/7052 (2013.01); A23V 2250/7056 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method for increasing energy levels of a subject, for reducing fatigue or drowsiness in a subject, or for increasing alertness in a subject, the method comprising administering to the subject a composition comprising about 1 mg to about 1000 mg of compound (14):

OG Complex Work Unit Chemistry
or a pharmaceutically or nutraceutically acceptable salt thereof.